Healthcare, Pharma & Life Sciences

Clearway Health Names Rishi Seth Chief Operating Officer

Image
Clearway Health Names Rishi Seth Chief Operating Officer

Boston – September 14, 2026 -- Clearway Health has appointed Rishi Seth as chief operating officer, adding a 20-year healthcare operations veteran to its executive leadership team as the specialty pharmacy sector undergoes rapid change.

Seth brings two decades of healthcare integration experience to Clearway Health

Seth most recently served as senior vice president of integration at Millennium Physician Group, one of the largest independent physician groups in the United States, where he led integration of new provider groups and strategic partnerships. He previously held senior leadership positions at Optum Health and Privia Health, focusing on multidisciplinary scalability across clinical operations, finance, technology, human resources and revenue cycle functions.

SlimSEB Ingredient Cuts Glucose Spike 16.9% in Clinical Trial

Image
SlimSEB Ingredient Cuts Glucose Spike 16.9% in Clinical Trial

Chino, Calif. – September 14, 2026 -- Specialty Enzymes & Probiotics has published dual-track research showing its ingredient SlimSEBTM reduces post-meal blood sugar spikes by 16.90% in a controlled human clinical trial, providing formulators with clinically backed data for glucose-support supplements.

Clinical trial confirms 16.90% reduction in glucose AUC

In a double-blind, randomized, placebo-controlled crossover trial, subjects supplemented with SlimSEBTM showed a 16.90% reduction in Area Under the Curve (AUC), a standard measure of post-prandial glycemic response. The result demonstrates statistically significant improvement in blood sugar control following meals.

Solstice Oncology Launches with $225M Series A for CTLA-4 Antibody

Image
Solstice Oncology Launches with $225M Series A for CTLA-4 Antibody

Cambridge, Mass. – September 14, 2026 -- Solstice Oncology has launched with a $225 million Series A financing led by RA Capital Management, with participation from Canaan Partners, Forbion and other investors, to advance a second-generation CTLA-4 antibody into earlier-stage cancer treatment.

Solstice secures $225 million to fund neoadjuvant immuno-oncology program

The clinical-stage company is focused on treating cancer in the neoadjuvant setting, before tumors have hardened resistance to therapy. Its lead candidate, porustobart, is a differentiated, Fc-enhanced CTLA-4 antibody being developed across two clinical indications, including microsatellite-stable (MSS) colon cancer and a second, undisclosed indication.

Partillion Bags $2.1M NIH Grant, Tops $8M in Federal Funding

Image
Partillion Bags $2.1M NIH Grant, Tops $8M in Federal Funding

Los Angeles – September 14, 2026 -- Partillion Bioscience has secured a two-year, $2.1 million NIH Small Business Innovation Research (SBIR) award from the National Institute of General Medical Sciences (NIGMS), pushing the company's total non-dilutive federal funding past $8 million.

Tenth SBIR grant matches private capital raised to date

The award, Partillion's 10th SBIR grant, was competitively secured through NIH's Direct-to-Phase II mechanism and roughly matches the company's private investment total, with no additional equity exchanged. The funding, awarded under grant number R44GM165220, will support development of the company's Cell-Cell-seq workflows over two years.

Cardiol Therapeutics to Present at H.C. Wainwright Conference Sept. 14

Image
Cardiol Therapeutics to Present at H.C. Wainwright Conference Sept. 14

Toronto – September 14, 2026 -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) will hold a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 14, 2026, at 10:30 a.m. EDT.

Cardiol schedules investor session at Lotte New York Palace Hotel

The session takes place in the Louis Room on the fourth floor of the venue. A live webcast will be available under the Events & Presentations section of the company's investor website.

Company advances Phase III trial for recurrent pericarditis treatment

Cardiol's lead candidate, CardiolRx, is being evaluated in the pivotal Phase III MAVERIC trial (NCT06708299) for recurrent pericarditis, following the completed Phase II MAvERIC-Pilot study (NCT05494788). The U.S. FDA has granted Orphan Drug Designation to CardiolRx for pericarditis, including the recurrent form of the disease.

Kazia Doses First Patient in Pediatric Brain Cancer Study

Image
Kazia Doses First Patient in Pediatric Brain Cancer Study

Sydney – September 14, 2026 -- Kazia Therapeutics Limited (NASDAQ: KZIA) has dosed the first patient in Arm A of PNOC035, a Phase 2 platform study testing paxalisib combined with gemcitabine for recurrent or progressive atypical teratoid/rhabdoid tumor (AT/RT), an aggressive pediatric brain cancer with no approved therapies.

Preclinical data showed the combination nearly quadrupled median survival in an AT/RT model

In an orthotopic AT/RT preclinical model, the paxalisib-gemcitabine combination extended median survival from 22 to 82.5 days (p0.0001) and showed complementary anti-tumor activity across multiple AT/RT cell lines. These findings, previously presented at ISPNO, AACR and Neuro-Oncology meetings, formed the scientific basis for advancing into the multicenter PNOC035 trial.

Galmed Rebrands to Eocene, Ends Yorkville Deal, Regains Nasdaq Compliance

Image
Galmed Rebrands to Eocene, Ends Yorkville Deal, Regains Nasdaq Compliance

Ramat Gan, Israel – September 13, 2026 -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) will rebrand as Eocene Ltd. and begin trading under the ticker EOCN on the Nasdaq Capital Market starting September 10, 2026, after terminating its $20 million standby equity purchase agreement with Yorkville and regaining compliance with Nasdaq's minimum bid price rule.

Company terminates $20 million Yorkville equity facility after raising $7.3 million

Galmed terminated its Standby Equity Purchase Agreement with YA II PN, Ltd. (Yorkville), effective September 8, 2026. The facility had provided up to $20 million in equity financing; the company raised approximately $7.3 million through the issuance of 437,947 ordinary shares before termination.

German Science Bodies Demand Cross-Ministry Health Prevention Strategy

Berlin – September 13, 2026 -- Four of Germany's leading scientific and health organizations have issued a joint call for a cross-departmental national prevention strategy, warning that roughly 40 percent of new cancer cases remain preventable despite decades of research.

Four organizations unite behind a joint policy statement

The Leopoldina National Academy of Sciences, the German Council of Science and Humanities (Wissenschaftsrat), the German Cancer Research Center (DKFZ) and German Cancer Aid (Deutsche Krebshilfe) presented a shared statement demanding that prevention be embedded across all policy fields -- including education, labor, transport, urban planning, environment and social affairs -- rather than confined to the health ministry alone.

Matica Bio Partners With Bondwell to Advance Texas Bioprocessing Tech

Image
Matica Bio Partners With Bondwell to Advance Texas Bioprocessing Tech

College Station, Texas – September 13, 2026 -- Matica Biotechnology, a Texas-based cell and gene therapy CDMO, has entered a collaboration with Bondwell Technologies to advance the latter's proprietary protein bioprocessing platform toward manufacturing readiness.

Matica Bio will provide development expertise to prepare Bondwell's technology for commercialization

Under the agreement, Matica Bio will support Bondwell Technologies, headquartered in College Station, in scaling its proprietary protein technology for bioprocessing and life science applications. The collaboration is designed to move Bondwell's platform closer to manufacturing readiness and future commercial deployment.

LUMA Vision Wins FDA Clearance for VERAFEYE Ahead of 2027 Launch

Image
LUMA Vision Wins FDA Clearance for VERAFEYE Ahead of 2027 Launch

Dublin – – September 13, 2026 -- LUMA Vision has secured an expanded FDA clearance for VERAFEYE, its procedural intelligence platform for minimally invasive cardiac procedures, moving the company closer to a planned commercial launch in early 2027.

VERAFEYE now unifies digital anatomy creation, catheter tracking, and guidance on a single platform

The new clearance allows VERAFEYE to reconstruct 3D models of the left and right atria with CT-like accuracy using a single 360° imaging catheter that captures raw ultrasound data. The platform lets physicians visualize and document ablation delivery directly on the anatomy while maintaining continuous tracking of both imaging and ablation catheters through electromagnetic tracking and automated imaging.